Individualized Care of Patients with COPD in the Hospital and Beyond




The burden and frequency of hospitalization for chronic obstructive pulmonary disease (COPD) remains high, requiring increased vigilance for changing symptoms and risk factors for exacerbations. It also requires that acute phase, emergency medicine, and inpatient healthcare providers (HCPs) are able to evaluate patient status and provide therapies matched to individual patient needs and severity levels. Gaps remain in HCPs’ ability to recognize individualized risk factors in patients with COPD and in collaboration between inpatient and outpatient providers. This activity was designed to promote awareness of the role of the emergency department and hospital in improving COPD care and to educate HCPs on the latest guideline recommendations for patient management and the many COPD therapies and devices available.


Fernando J. Martinez, MD, MS
Chief, Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York


Release date: December 18, 2020
Expiration date: December 18, 2021
Estimated time to complete activity: 1.0 hours



This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists involved in the management of patients with COPD in the hospital and transitional care setting.


Upon completion of this educational activity, participants should be able to:

  • Describe the characteristics of patients who present to the emergency department (ED) for COPD exacerbations, which underscore the need for increased diagnostic vigilance in the hospital setting
  • Discuss how to utilize GOLD therapeutic strategy and other emerging guidance to diagnose and assess COPD severity in patients who present to the ED or are hospitalized
  • Identify recent therapeutic strategy updates and the treatable traits approach for the management of COPD
  • Discuss available therapies for COPD and available evidence for their use in patients presenting to the ED or hospitalized for COPD

GOLD = Global Initiative for Chronic Obstructive Lung Disease


There are no fees for participating and receiving CME/CE credit for this activity.

During the period of December 18, 2020 through December 18, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.




Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this free continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-20-312-H01-P.)

This is a knowledge-based activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

For information about ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.


Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity and their spouse/life partner to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, and Ashley Marostica.

Faculty Disclosures

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant, Promedior/Roche, Veracyte
Data Safety Monitoring Board: Boehringer Ingelheim, GlaxoSmithKline


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.


This activity is supported by educational grants from AstraZeneca Pharmaceuticals.

Continue to Pretest